Share on StockTwits

Alcobra Ltd (NASDAQ:ADHD)‘s stock had its “top pick” rating reiterated by equities research analysts at Aegis in a research note issued to investors on Thursday, Analyst RN reports.

The analysts wrote, “compelling value proposition” in Alcobra shares. The analyst commented on value drivers in 2014 including the enrollment in the first or two Phase 3 trials of MG01CI in the first quarter, the second Phase 3 trial with the comparison to Strattera in the second half of 2014, and the initial Phase 2 trial of MG01CI in pediatric patients over the next 4-6 months. Aegis Capital added that Alcobra has the best-in-class product profile with the rapid onset on action for MG01CI. Selvaraju wrote, “In our view, MG01CI could have a best- in-class efficacy profile for treatment of PI-ADHD (also known as attention deficit disorder, or ADD), which comprises over 40% of all ADHD sufferers. The drug has also been shown to be safe and well-tolerated in several clinical trials to date.” Aegis Capital placed extra emphasis on Alcobra obtaining the Orphan Drug status for MG01CI from the FDA in Fragile X Syndrome (FXS). This award “confers seven years of automatic market exclusivity and a rapid path to commercialization on MG01CI early in its development process as an FXS drug.”

Alcobra Ltd (NASDAQ:ADHD) traded up 0.50% during mid-day trading on Thursday, hitting $18.09. The stock had a trading volume of 133,318 shares. Alcobra Ltd has a 52 week low of $6.50 and a 52 week high of $26.96. The stock has a 50-day moving average of $17.11 and a 200-day moving average of $14.7. The company’s market cap is $201.3 million.

Alcobra Ltd (NASDAQ:ADHD) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.28) earnings per share (EPS) for the quarter.

Separately, analysts at Stifel Nicolaus initiated coverage on shares of Alcobra Ltd in a research note to investors on Wednesday, December 4th. They set a “buy” rating and a $27.00 price target on the stock.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (NASDAQ:ADHD), a common and morbid neuropsychiatric condition in children and adults.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.